Marty Bennett, MD
Psychiatry · Addison, TXNPI 1487616272
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,425,854 of the $1,844,259 with a category attached, or 77.3%. 30 manufacturers reported payments, led by AbbVie at 43.6% of the total. 2025 is the largest year on record at $398,170, 3.3 times the $119,631 reported in 2019. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,807 payments — averaging $484.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$805K
- Johnson & Johnson$518K
- Axsome Therapeutics, Inc.$185K
- Alkermes, Inc.$140K
- Vanda Pharmaceuticals Inc.$65K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$58K
- plus $74K from 24 others
What the payments were for
- Consulting fees$163,2879%
- Speaking & faculty fees$1,425,85477%
- Travel & lodging$204,51611%
- Food & beverage$50,5363%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 1,458 | $804,526 |
| Johnson & Johnson(3 entities) | 865 | $518,164 |
| Axsome Therapeutics, Inc. | 298 | $184,866 |
| Alkermes, Inc. | 282 | $139,937 |
| Vanda Pharmaceuticals Inc. | 91 | $64,881 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 157 | $58,324 |
| Otsuka America Pharmaceutical, Inc. | 183 | $38,745 |
| Supernus Pharmaceuticals, Inc. | 53 | $28,740 |
| Lundbeck LLC | 98 | $1,330 |
| Neurocrine Biosciences, Inc. | 73 | $1,208 |
| Teva Pharmaceuticals USA, Inc. | 19 | $450 |
| Noven Therapeutics, LLC | 23 | $340 |
| Corium, LLC | 24 | $337 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $317 |
| Ironshore Pharmaceuticals Inc. | 18 | $306 |
| Sunovion Pharmaceuticals Inc. | 43 | $293 |
| E.r. Squibb & Sons, L.L.C. | 19 | $293 |
| Jazz Pharmaceuticals Inc. | 13 | $180 |
| Avanir Pharmaceuticals, Inc. | 20 | $177 |
| Bausch Health US, LLC | 10 | $160 |
| Idorsia Pharmaceuticals US Inc | 8 | $160 |
| Eisai Inc. | 11 | $138 |
| Tris Pharma Inc | 5 | $99 |
| Adlon Therapeutics L.p. | 6 | $86 |
| Almatica Pharma LLC | 3 | $64 |
| Neos Therapeutics, LP | 3 | $55 |
| Validus Pharmaceuticals LLC | 1 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,844,259 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 28 | $10,883 |
| Adderall XrDextroamphetamine/Amphetamine | 14 | $6,304 |
| Lisdexamfetamine Dimesylate | 19 | $4,697 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 79 | $2,890 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 24 | $1,611 |
| Trazodone Hcl | 20 | $1,536 |
| Vilazodone Hcl | 11 | $1,256 |
| Divalproex Sodium ErDivalproex Sodium | 18 | $967 |
| Bupropion XlBupropion Hcl | 25 | $948 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $779 |
| Clonazepam | 42 | $494 |
| Mirtazapine | 11 | $306 |
| Amitriptyline Hcl | 12 | $223 |
| Fluoxetine Hcl | 16 | $215 |
| Paroxetine Hcl | 11 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $317 | $10,88328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Addison
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.